FIELD: pharmaceuticals.
SUBSTANCE: group of inventions refers to compounds and compositions which represent a specific inhibitor of ANGPTL3, as well as to a method for reducing the expression of mRNA and protein ANGPTL3 in an animal.
EFFECT: disclosed antisense compounds have improved activity in liver cells in vivo; such methods, compounds and compositions are suitable for treating, preventing, delaying or relieving any one or more of the cardiovascular disease and/or metabolic disease or its symptom in an individual in need thereof.
30 cl, 239 tbl, 133 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR MODULATION OF HBV AND TTR EXPRESSION | 2014 |
|
RU2782034C2 |
| MODULATION OF PREKALLIKREIN (PKK) EXPRESSION | 2014 |
|
RU2712559C2 |
| MODULATION OF FACTOR 11 EXPRESSION | 2014 |
|
RU2739594C2 |
| COMPOSITION FOR MODULATION OF C90RF72 EXPRESSION | 2014 |
|
RU2748426C2 |
| COMPOUND FOR MODULATION OF C9ORF72 GENE EXPRESSION AND USE THEREOF | 2013 |
|
RU2730677C2 |
| COMPOSITIONS FOR MODULATING TAU PROTEIN EXPRESSION | 2014 |
|
RU2735551C2 |
| COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF TAU | 2014 |
|
RU2745324C2 |
| COMPOSITIONS FOR MODULATING EXPRESSION OF TAU PROTEIN | 2014 |
|
RU2823361C1 |
| CONJUGATES AND THEIR OBTAINING AND APPLICATION | 2018 |
|
RU2795400C2 |
| METHODS AND COMPOSITIONS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2013 |
|
RU2748495C2 |
